Equity Components [Axis] Series A and Z Preferred Stock Common Stock Additional Paid-In Capital Accumulated Deficit Fair Value, Hierarchy [Axis] Level 1 Level 2 Exercise Price Range [Axis] Option 1 Option 2 Nature of Expense [Axis] General and Administrative Expenses Research and Development Expenses Related Party [Axis] Chief Executive Officer Chief Scientific Officer Executive Chairman of the Board of Directors Income Tax Authority, Name [Axis] State Stockholder and Board Member Accumulated Other Comprehensive Loss Range [Axis] Minimum Maximum Document And Entity Information Entity Registrant Name Document Type Document Period End Date Amendment Flag Amendment Description Entity Central Index Key Entity Filer Category Entity Small Business Entity Emerging Growth Company Entity Ex Transition Period Statement of Financial Position [Abstract] Assets Current assets: Cash and cash equivalents Deferred offering costs Prepaid expenses and other current assets Total current assets Restricted cash Total assets Liabilities and Stockholders' Equity Current liabilities: Accounts payable, accrued expenses and other current liabilities Total current liabilities Long term liabilities Total liabilities Commitments and contingencies Stockholders' equity: Common stock Additional paid-in capital Accumulated deficit Accumulated other comprehensive loss Total stockholders equity Total liabilities and stockholders' equity Common stock, par value Common stock, authorized Common stock, issued Common stock, outstanding Income Statement [Abstract] Revenues Operating expenses: Research and development In-process research and development General and administrative Total operating expenses Loss from operations Other income: Interest and other income Loss before income tax benefit Income tax benefit Net loss Other comprehensive income (loss): Foreign currency translation loss Comprehensive loss Net loss per share: Basic and diluted Weighted average shares outstanding: Basic and diluted Statement [Table] Statement [Line Items] Beginning balance, shares Beginning balance, amount Conversion of preferred stock to common stock, shares Conversion of preferred stock to common stock, amount Issuance of common stock at $6 per share for cash, net of $32,400 issuance costs, shares Issuance of common stock at $6 per share for cash, net of $32,400 issuance costs, amount Tactic Pharma shares surrendered, shares Tactic Pharma shares surrendered, amount Shares issued in Gem transaction, net of issuance costs of $169,257, shares Shares issued in Gem transaction, net of issuance costs of $169,257, amount Non-cash stock compensation Net loss Other comprehensive gain (loss) Ending balance, shares Ending balance, amount Statement of Cash Flows [Abstract] Cash flows from operating activities: Adjustments to reconcile net loss to net cash used in operating activities: Stock-based compensation (non-cash) In process research and development (non-cash) Changes in operating assets and liabilities, net Prepaid expenses and other current assets Accounts payable, accrued expenses and other current liabilities Net cash used in operating activities Cash flows from financing activities: Cash received from Gem, net of $169,257 of transaction costs Proceeds from the sale of common stock, net of $32,400 of issuance costs Deferred offering costs Net cash provided by financing activities Effect of exchange rates on cash, cash equivalents, and restricted cash Net increase in cash, cash equivalents and restricted cash Cash, cash equivalents and restricted cash at beginning of period Cash, cash equivalents and restricted cash at end of period Supplemental disclosure of non-cash items for cash flow information: Value of shares issued in Gem transaction Organization, Consolidation and Presentation of Financial Statements [Abstract] Nature of Business and Liquidity Accounting Policies [Abstract] Significant Accounting Policies Stockholders' Equity Note [Abstract] Capital Stock Share-based Payment Arrangement [Abstract] Stock Option Plan Development And Collaboration Agreements Development and Collaboration Agreements Business Combinations [Abstract] The Gem Transaction Related Party Transactions [Abstract] Related Party Transactions Income Tax Disclosure [Abstract] Income Taxes Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Basis of Presentation Functional Currency Comprehensive Loss Use of Estimates Going Concern Assessment Cash Equivalents Deferred Offering Costs Restricted Cash Prepaid Expenses Concentration of Credit Risk Fair Value of Financial Instruments Assets and Liabilities Measured at Fair Value on a Recurring Basis Net Loss per Share Research and Development Expenses In-process Research and Development Collaborative Arrangements Licensing Agreements Patent Costs Leases Income Taxes Stock-Based Compensation Recent Accounting Pronouncements Assets and liabilities measured at fair value on a recurring basis Stock option activity Summary of options outstanding Assets acquired Provision for income taxes Effective income tax rate reconciliation Deferred tax assets and liabilities Future lease commitments State of incorporation Date of incorporation Accumulated loss Fair Value Hierarchy and NAV [Axis] Cash equivalents Total Potentially dilutive securities Stock options available outstanding, beginning Stock options available, option pool Stock options available, granted Stock options available, forfeited Stock options available, exercised Stock options available outstanding, ending Stock options outstanding, beginning Stock options, option pool Stock options, granted Stock options, forfeited Stock options, exercised Stock options outstanding, ending Weighted average exercise price outstanding, beginning Weighted average exercise price, option pool Weighted average exercise price, granted Weighted average exercise price, forfeited Weighted average exercise price, exercised Weighted average exercise price outstanding, ending Exercise price Number of shares outstanding Weighted average remaining contractual life Number of shares fully vested and exercisable Weighted average remaining contractual life Statistical Measurement [Axis] Employee and non-employee director stock-based compensation expense Stock-based compensation expense for non-employees Expected term Volatility Dividends Risk free interest rate Weighted average grant date fair Fair value of shares vested Aggregate intrinsic value of outstanding stock options Unamortized unvested balance of stock base compensation Unamortized unvested balance of stock base compensation, period Cash recorded on the Company's Balance Sheet Assembled Workforce recorded as In-process Research and Development Expense on the Company's Statement of Operations Camsirubicin (GPX-150) recorded as In-process Research and Development Expense on the Company's Statement of Operations Total Gem Transaction Related party transaction Legal fees Current: Federal State Total current Deferred: Federal State Total deferred Full valuation allowance Total provision Federal income tax State income taxes, less federal benefit Tax credits Permanent differences Change in valuation allowance Other (Release of VA) Effective tax rate benefit (expense) Deferred tax assets: Net operating loss carryforwards Tax credit carryforwards Stock compensation Intangible asset basis differences Gross deferred tax assets Valuation allowance Total deferred tax assets, net of valuation allowance Deferred tax liabilities: Net deferred tax liability Net deferred taxes Change in valuation allowance Net operating loss carryforwards Net operating loss carryforwards expiration Research and development credit carryforwards 2019 Thereafter Total future lease payments Operating lease expense Assets, Current Assets [Default Label] Liabilities, Current Liabilities Stockholders' Equity Attributable to Parent Liabilities and Equity Operating Expenses Operating Income (Loss) Deferred Income Tax Expense (Benefit) Comprehensive Income (Loss), Net of Tax, Attributable to Parent Weighted Average Number of Shares Outstanding, Basic and Diluted Shares, Outstanding Increase (Decrease) in Prepaid Expense and Other Assets Increase (Decrease) in Accounts Payable and Accrued Liabilities Net Cash Provided by (Used in) Operating Activities Increase (Decrease) in Deferred Charges Net Cash Provided by (Used in) Financing Activities Cash and Cash Equivalents, Period Increase (Decrease) Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Research and Development Expense, Policy [Policy Text Block] Income Tax, Policy [Policy Text Block] Cash ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableOutstandingNumber Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets Current State and Local Tax Expense (Benefit) Current Income Tax Expense (Benefit) Deferred Federal Income Tax Expense (Benefit) Deferred Federal, State and Local, Tax Expense (Benefit) IncomeTaxExpenseBenefitValuationAllowance Income Tax Expense (Benefit) Effective Income Tax Rate Reconciliation, Percent Deferred Tax Assets, Gross Deferred Tax Assets, Valuation Allowance Deferred Tax Assets, Net of Valuation Allowance Deferred Tax Liabilities, Net Deferred Tax Assets, Net Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount Operating Loss Carryforwards Operating Leases, Future Minimum Payments Due